Are Patients With End-Stage Liver Disease Maximally Vasodilated?: Insights From Rubidium-82 PET Dilatory Perfusion

JACC Cardiovasc Imaging. 2019 Dec;12(12):2583-2584. doi: 10.1016/j.jcmg.2019.07.008. Epub 2019 Sep 18.

Authors

Ahmed Aljizeeri, Mousa Alali Alfaris, Dalia Ahmed, Jabir Farea, Awadelkarim Elneama, Ihab Suliman, Mohsen Alharthi, Amjad Ahmed, Ahmed Alsaileek, Mouaz Al-Mallah

PMID: 31542532
DOI: 10.1016/j.jcmg.2019.07.008

No abstract available

Publication types

Letter

MeSH terms

Aged
Coronary Artery Disease / complications
Coronary Artery Disease / diagnostic imaging*
Coronary Artery Disease / physiopathology
Dipyridamole / administration & dosage*
End Stage Liver Disease / complications*
End Stage Liver Disease / diagnosis
End Stage Liver Disease / physiopathology
Female
Humans
Male
Middle Aged
Myocardial Perfusion Imaging*
Positron Emission Tomography Computed Tomography*
Predictive Value of Tests
Purines / administration & dosage*
Pyrazoles / administration & dosage*
Radiopharmaceuticals / administration & dosage*
Retrospective Studies
Rubidium Radioisotopes / administration & dosage*
Vasodilation*
Vasodilator Agents / administration & dosage*

Substances

Purines
Pyrazoles
Radiopharmaceuticals
Rubidium Radioisotopes
Vasodilator Agents
regadenoson
Dipyridamole